Antibody Drug Therapy

Conventional anticancer therapeutics often suffer from lack of specificity, resulting in toxicities to normal healthy tissues and poor therapeutic index. Antibody-drug conjugates (ADCs) constitute a therapeutic modality in which a cytotoxic agent is chemically linked to an antibody (Ab) that recognizes a tumor-associated antigen. The basic strategy underlying ADC technology is to combine the target selectivity of mAbs with the potency of cytotoxic agents, such as certain natural products and synthetic molecules, with the goal of generating therapeutic drugs that are highly efficacious but also safe. The ADC platform currently includes a growing repertoire of cytotoxic payloads, linker technologies and conjugation methods. Two ADCs have recently received FDA approval and more than 30 are in clinical development. This meeting aims to highlight advances in ADC research, clinical development and regulatory perspectives.

  • Innovative Antibody drugs in Clinical Trail and Development
  • Antibody-drug Conjugate (ADC) Discovery and Development
  • Bispecific and Multispecific antibody discovery and development
  • Challenges and New Opportunities with Antibody and Protein Drugs
  • Novel Antibody and Biologic Drug Targets

Related Conference of Antibody Drug Therapy

June 13-14, 2019 |

10th European Immunology Conference

Berlin, Germany
July 29-30 2019

6th International Conference on Parasitology & Microbiology

Amsterdam, Netherlands
July 29-30, 2019

11th Global Summit on Immunology and Cell Biology

Sydney, Australia
November 12-13, 2019

13th International Congress on Autoimmunity

Brisbane, Australia
November 21-22, 2019

World Conference on Vaccine and Immunology

Dubai, UAE
November 25-26 , 2019

Global meet on Immunology and Molecular Biology

Paris, France
November 28-29, 2019

International Conference on Vaccines and Immune Response

Helsinki, Finland

Antibody Drug Therapy Conference Speakers

Recommended Sessions

Related Journals

Are you interested in